Treasurer Of The State Of North Carolina Mirati Therapeutics, Inc. Transaction History

Treasurer Of The State Of North Carolina

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$0.0 - $59.28 $0 - $1.44 Million	-24,258 Closed	0 $0
Q4 2023 Feb 12, 2024	BUY	$41.99 - $62.38 $176,777 - $262,619	4,210 Added 21.0%	24,258 $1.43 Million
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $3,058 - $4,988	110 Added 0.55%	20,048 $873,000
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $15,535 - $21,280	430 Added 2.2%	19,938 $720,000
Q1 2023 May 04, 2023	BUY	$36.54 - $54.26 $5,115 - $7,596	140 Added 0.72%	19,508 $725,000
Q4 2022 Feb 09, 2023	BUY	$41.27 - $98.62 $38,381 - $91,716	930 Added 5.04%	19,368 $878,000
Q3 2022 Nov 08, 2022	BUY	$59.5 - $86.7 $14,280 - $20,808	240 Added 1.32%	18,438 $1.29 Million
Q2 2022 Aug 02, 2022	BUY	$39.16 - $88.71 $108,512 - $245,815	2,771 Added 17.96%	18,198 $1.22 Million
Q1 2022 May 10, 2022	BUY	$75.82 - $150.97 $18,803 - $37,440	248 Added 1.63%	15,427 $1.27 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $137,290 - $197,901	1,040 Added 7.36%	15,179 $2.23 Million
Q3 2021 Nov 03, 2021	BUY	$132.13 - $177.45 $63,290 - $84,998	479 Added 3.51%	14,139 $2.5 Million
Q2 2021 Aug 13, 2021	BUY	$144.0 - $179.73 $1.97 Million - $2.46 Million	13,660 New	13,660 $2.21 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Treasurer Of The State Of North Carolina, based on Form 13F filings with the SEC.

Stay updated on Treasurer Of The State Of North Carolina with notifications on news.